Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies.
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange.
COVID-19 might have forced pharma to finally fully embrace digital comms, but it’s been a steep learning curve and expertise varies across the industry.
